Neuren announces A$50m on-market share buy-back program
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Q3 2024 update
- PRV sold for US$150m - Neuren to receive one third
- DAYBUE receives marketing authorization in Canada
- NEU continues PMS P3 preparations after positive FDA meeting
- Phase 2 trial shows significant improvements in Angelman
Later from Neuren Pharmaceuticals
- Trofinetide marketing application submitted in Europe
- Priority Review Voucher sale proceeds received
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Neuren receives Rare Pediatric Disease Designation from FDA
- DAYBUE (trofinetide) 2024 net sales US$348 million
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals